GlassScriptPhysician profile
Chad C Cherington
NPI 1285952390
$36,160.14
in general payments reported to CMS, 2019-2025
78 companies · $3,629 in 2025
The $3,629 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,578 · 2020: $3,534 · 2021: $6,688 · 2022: $6,318 · 2023: $6,656 · 2024: $3,757 · 2025: $3,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,987 · Food and Beverage: $6,710 · Education: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,987.00 |
| Food and Beverage | $6,710.26 |
| Education | $344.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $3,150.46 | 2019-2025 | |
| Global Blood Therapeutics, INC. | $2,651.07 | 2021-2022 | |
| Kyowa Kirin, INC. | $2,536.08 | 2019 | |
| Springworks Therapeutics, INC. | $2,088.55 | 2024-2025 | Ogsiveo |
| Servier Pharmaceuticals LLC | $1,861.43 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $1,766.59 | 2022-2025 | Fotivda |
| Astellas Pharma Global Development | $1,427.07 | 2024 | Padcev |
| Novartis Pharmaceuticals Corporation | $1,348.90 | 2019-2025 | |
| Janssen Biotech, INC. | $1,311.56 | 2019-2025 | Darzalex, Erleada, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $1,225.68 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Exelixis INC. | $1,181.35 | 2019-2023 | Cabometyx |
| Pfizer INC. | $1,075.72 | 2019-2025 | |
| Celgene Corporation | $1,037.15 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $971.38 | 2019-2025 | Opdivo, Opdualag |
| Genentech USA, INC. | $834.74 | 2019-2025 | Tecentriq, Columvi, Polivy |
Show all 78 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $777.66 | 2019-2025 | Xtandi |
| Merck Sharp & Dohme LLC | $730.91 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genzyme Corporation | $667.13 | 2019-2024 | |
| Amgen INC. | $660.15 | 2019-2023 | Lumakras, Kyprolis, Nplate |
| Seagen INC. | $611.90 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Daiichi Sankyo INC. | $563.05 | 2020-2025 | Enhertu, Injectafer |
| Regeneron Healthcare Solutions, INC. | $534.58 | 2021-2025 | Libtayo |
| Abbvie INC. | $524.74 | 2019-2025 | Creon, Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $524.12 | 2019-2023 | Imbruvica, Epkinly |
| Eisai INC. | $399.22 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $388.20 | 2019-2024 | Ninlaro, Iclusig, Alunbrig |
| Rigel Pharmaceuticals, INC. | $340.76 | 2019-2025 | Rezlidhia, Gavreto, Tavalisse |
| Glaxosmithkline, LLC. | $335.51 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Incyte Corporation | $308.17 | 2019-2025 | Jakafi |
| Gilead Sciences, INC. | $290.25 | 2019-2023 | Trodelvy |
| Array Biopharma INC | $266.32 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Lilly USA, LLC | $237.72 | 2019-2023 | Verzenio |
| Kite Pharma, INC. | $203.10 | 2020-2025 | Yescarta |
| Novocure Gmbh | $200.00 | 2022 | |
| Sirtex Medical INC | $179.79 | 2023 | Sir-Spheres Microspheres |
| Ipsen Biopharmaceuticals, INC | $176.86 | 2019-2024 | Onivyde |
| Myovant Sciences INC. | $163.51 | 2021-2022 | |
| Emd Serono, INC. | $158.54 | 2019-2023 | Tepmetko, Bavencio |
| Jazz Pharmaceuticals INC. | $156.02 | 2020-2022 | |
| Dova Pharmaceuticals | $149.81 | 2019-2021 | |
| Puma Biotechnology, INC. | $135.41 | 2019-2023 | |
| Blueprint Medicines Corporation | $107.82 | 2020-2022 | |
| Karyopharm Therapeutics INC. | $105.35 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $101.71 | 2019-2025 | Ultomiris |
| Taiho Oncology, INC. | $92.71 | 2020-2025 | |
| Intuitive Surgical, INC. | $92.59 | 2022 | |
| Penumbra, INC. | $91.22 | 2024 | Indigo System |
| Sobi, INC | $88.54 | 2022-2024 | |
| Tersera Therapeutics LLC | $85.32 | 2021-2024 | Zoladex |
| Janssen Scientific Affairs, LLC | $83.50 | 2025 | Erleada, Balversa, Akeega |
| Epizyme, INC. | $83.31 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $79.25 | 2020-2022 | |
| Mirati Therapeutics, INC. | $73.62 | 2023-2024 | Krazati |
| Janssen Pharmaceuticals, INC | $71.96 | 2019-2021 | |
| Clovis Oncology, INC. | $67.68 | 2019-2021 | |
| Organon LLC | $65.07 | 2021-2022 | |
| Cti Biopharma Corp. | $61.87 | 2023 | Vonjo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.79 | 2019-2021 | |
| Medexus Pharma, INC. | $56.69 | 2021 | |
| Beigene USA, INC. | $50.13 | 2023 | Brukinsa |
| Iovance Biotherapeutics, INC. | $47.66 | 2025 | Amtagvi |
| Adaptive Biotechnologies Corporation | $39.79 | 2022-2025 | Clonoseq |
| Aurobindo Pharma USA, INC. | $38.53 | 2019-2020 | |
| G1 Therapeutics, INC. | $38.11 | 2022 | |
| Verastem, INC. | $36.34 | 2019-2020 | |
| Chiesi USA, INC. | $35.09 | 2021-2022 | |
| Beone Medicines USA, INC. | $29.97 | 2025 | Brukinsa |
| Viiv Healthcare Company | $29.43 | 2025 | Cabenuva |
| Mayne Pharma Commercial LLC | $25.15 | 2022 | |
| Sumitomo Pharma America, INC. | $23.52 | 2025 | Orgovyx |
| Pharmaessentia USA Corporation | $23.09 | 2025 | Besremi |
| Lexicon Pharmaceuticals, INC. | $23.02 | 2019 | |
| Spectrum Pharmaceuticals INC. | $21.07 | 2019 | |
| Teleflex LLC | $19.63 | 2021 | |
| Mylan Institutional INC. | $17.53 | 2019 | |
| Verity Pharmaceuticals INC. | $17.03 | 2024 | Trelstar |
| Morphosys, US INC. | $15.64 | 2022 | |
| Eusa Pharma (US) LLC | $13.25 | 2020 |
Drugs and devices associated with these payments
Nubeqa $2,797Ogsiveo $2,089Fotivda $1,708Padcev $1,528Libtayo $401Reblozyl $325Xtandi $287Keytruda $270Enhertu $262Imbruvica $233Opdivo $211Darzalex $193Epkinly $188Sir-Spheres Microspheres $180Tukysa $180Orgovyx $164Venclexta $158Erleada $150Ibrance $141Talzenna $140Jemperli $133Lynparza $130Balversa $129Akeega $120Kisqali $119Zejula $119Imfinzi $116Tecentriq $114Fabhalta $101Indigo System $91.22Lenvima $89.75Braftovi $85.34Mektovi $85.34Brukinsa $80.10Inlyta $76.70Oxbryta $75.81Lunsumio $75.67Columvi $75.67Polivy $75.67Lorbrena $75.46Krazati $73.62Ultomiris $70.20Xofigo $69.76Vitrakvi $62.06Stivarga $62.06Vonjo $61.87Jakafi $59.58Bavencio $56.60Opdualag $54.34Comirnaty $52.55Keytruda Qlex $51.92Yescarta $51.50Tecvayli $51.02Emrelis $49.88Amtagvi $47.66Enjaymo $46.51Ninlaro $46.32Gavreto $44.62Paxlovid $40.52Tavalisse $39.89Rezlidhia $39.89Jevtana $39.20Welireg $38.84Inqovi $37.90Lonsurf $37.90Doptelet $37.44Ojjaara $34.39Adcetris $34.14Tepmetko $31.48Synagis $31.05Cerdelga $31.04Cabometyx $29.58Cabenuva $29.43Clonoseq $27.02Xalkori $26.24Trodelvy $25.77Tabrecta $25.51Blenrep $23.41Injectafer $23.10Besremi $23.09Iclusig $22.93Asparlas $22.91Sarclisa $22.69Creon $22.34Bosulif $21.33Verzenio $20.90Alecensa $20.37Rozlytrek $20.37Zoladex $20.09Voranigo $19.43Scemblix $18.91Alunbrig $18.78Lumakras $18.33Onivyde $17.79Pluvicto $17.68Kyprolis $17.52Trelstar $17.03Promacta $16.59Phesgo $16.37Itovebi $16.37
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Cherington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.